Mirati Therapeutics announced that it intends to offer and sell $250M of shares of its common stock, and, to certain investors, pre-funded warrants to purchase shares of common stock, in an underwritten public offering. Goldman Sachs & Co. is acting as the book-running manager for the proposed offering. Leerink Partners is acting as financial advisor for the proposed offering.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MRTX:
- Mirati Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Updates
- MRTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Mirati Therapeutics initiated with an Underperform at Scotiabank
- Mirati Therapeutics price target lowered to $60 from $104 at Guggenheim
- Mirati Therapeutics price target lowered to $45 from $51 at B. Riley